REZLIDHIA (olutasidenib)

About Rigel Pharmaceuticals

Rigel Pharmaceuticals has successfully transitioned from a discovery-focused research organization to a fully integrated commercial biotech with two marketed products: TAVALISSE® for chronic immune thrombocytopenia (ITP) and REZLIDHIA® for relapsed/refractory AML with an IDH1 mutation. The company's strategy centers on expanding the labels of its commercial assets, advancing its clinical pipeline in hematology-oncology and immunology, and pursuing strategic collaborations. With a seasoned leadership team and a focus on dysregulated signaling pathways, Rigel aims to build a sustainable portfolio in niche hematologic and oncologic markets.

Therapeutic Areas